Oncology

The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
 
[[thumbnail_alt_text]]
Experts discuss who and what is involved in adding subcutaneous formulations to the formulary.
[[thumbnail_alt_text]]
Researchers note that a metabolic imbalance in some patients with cancer following treatment with nivolumab is associated with shorter survival.
[[thumbnail_alt_text]]
Pegilodecakin in combination with pembrolizumab and nivolumab achieved measurable responses in patients with non-small cell lung cancer and kidney cancer.
[[thumbnail_alt_text]]
A panel of experts reviews the benefits of subcutaneous dosing from the patient perspective.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
 
[[thumbnail_alt_text]]
Factors that inform the decision to stratify patients to subcutaneous formulations.
[[thumbnail_alt_text]]
After participating in a sleep-education program, 41% of participants who survived cancer had their insomnia successfully treated.
[[thumbnail_alt_text]]
Top news of the week from Specialty Pharmacy Times.
[[thumbnail_alt_text]]
Glenmark Pharmaceuticals has received FDA approval for abiraterone acetate tablets USP, 250 mg, a generic of Janssen's Zytiga tablets, 250 mg.1
[[thumbnail_alt_text]]
Potential clinical and financial causes for hesitation in the transition to subcutaneous dosing are addressed.
[[thumbnail_alt_text]]
Study suggests that blocking a signaling pathway that includes the inflammatory factor CXCL10-CXCR3 may prevent brain metastasis.
+ Load More